Last updated: February 14, 2026
Overview
Propylthiouracil (PTU) is an antithyroid drug approved for treating hyperthyroidism, primarily Graves' disease. It blocks thyroid hormone synthesis by inhibiting thyroid peroxidase and reduces peripheral conversion of T4 to T3. PTU has seen declining use in favor of other medications, raising questions about market viability.
Regulatory and Market Status
- Approved Indications: Treatment for hyperthyroidism, thyroid storm.
- Regulatory Restrictions: In some markets, PTU carries black box warnings due to hepatotoxicity risks. The FDA issued a label change in 2010 warning against its use as a first-line therapy in certain populations.
- Market Withdrawal: Some countries have limited or phased out PTU due to safety concerns. In the US, its use decreased significantly; it remains available but limited to specific cases.
Market Size and Trends
- Global Market Size (2022): Estimated at $240 million, with a projected annual compound growth rate (CAGR) of less than 1% through 2027.
- US Market: Dominates, with an approximate 65% share. The market value in the US estimated at $156 million in 2022.
- Major Market Drivers:
- Limited first-line options (methimazole preferred).
- Use in special populations, such as pregnant women, where PTU is sometimes preferred over methimazole despite safety concerns.
- Routine replacement by more targeted or safer therapies impacts demand.
Competitive Landscape
- Key Players:
- Pharmaceutical companies manufacturing generic PTU.
- Limited branded options; most sales are generics.
- Alternatives: Methimazole, carbimazole, radioactive iodine therapy, thyroidectomy.
- Market share: Generics hold over 95% of the market, with no significant proprietary competition.
Development and Patent Outlook
- Patents: Many patents expired decades ago. No recent patent filings for PTU itself.
- Research and Development: Minimal, given safety concerns and market decline. Focus shifts toward longer-term or more targeted drugs for hyperthyroidism, such as novel anti-thyroid agents or immunotherapies.
Pricing and Revenue Trends
- Pricing: PTU remains inexpensive; average wholesale prices (AWP) hover around $0.10–$0.20 per tablet.
- Revenue Trends: Declined from a peak of approximately $300 million globally in the early 2000s; now stable or declining marginally due to reduced demand.
Key Challenges
- Safety profile limits prescribing, especially in countries with strict drug safety regulations.
- Competition from more effective or safer drugs reduces market share.
- Limited innovation reduces potential for growth or market expansion.
Future Outlook
- The market for PTU is unlikely to grow. Monitored mainly for niche uses (pregnancy, specific patient cases).
- It faces obsolescence as newer therapies with better safety and efficacy profiles enter the market.
- Continued decline observed as guidelines favor other therapies and safety concerns dominate prescribing behavior.
Key Takeaways
- PTU's market is shrinking due to safety issues and shifting treatment paradigms toward alternative therapies.
- The global market remains small, with a slight CAGR approaching zero through 2027.
- Generic competition dominates, with no recent patents or innovation activity.
- Revenue and pricing stability persist but do not indicate growth prospects.
- Regulatory constraints and safety profiles hamper market expansion, confining PTU to specialized uses.
FAQs
1. Why has PTU experienced a decline in the market?
It has a risk of hepatotoxicity, leading to regulatory restrictions and a preference for safer alternatives like methimazole.
2. Are there any attempts to develop new formulations of PTU?
No significant R&D efforts are underway due to safety concerns and limited commercial incentives.
3. What are the primary substitutes for PTU?
Methimazole, radioactive iodine, and thyroidectomy are the main alternatives.
4. How does regulatory safety information impact PTU’s market?
The FDA and other agencies' warnings limit prescribing, especially in populations at higher risk for liver injury.
5. What is the outlook for PTU’s market in the next five years?
It remains stable but declines gradually, with negligible growth prospects.
References
[1] U.S. Food and Drug Administration. Label Change for Propylthiouracil (PTU). 2010.
[2] MarketResearch.com. Global Market for Antithyroid Drugs, 2022.
[3] Bouvier et al. Safety Profile of Propylthiouracil: A Review. Thyroid. 2018.
